The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-18. Anything still debated is marked as such rather than presented as settled.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
retatrutide 是一种人工合成的多肽，设计目标是同时作用于 GIP、GLP-1 与胰高血糖素三种受体。这种三重激动设计试图把多条代谢通路的调节整合进单一分子，而不是只依赖一种肠促胰素受体。分子骨架以天然肽序列为基础，经过非天然氨基酸替换和脂肪酸侧链修饰，以获得更长的作用时间。该方向属于多受体激动剂研究的一部分，与双重激动剂的工作并行推进。
三种受体在能量平衡中的分工并不相同：GLP-1 与 GIP 受体主要参与胰岛素分泌和食欲调节，胰高血糖素受体则与能量消耗及肝糖输出相关。同时激活三者可能产生叠加效应，也可能出现相互制约，具体结果取决于受体亲和力与组织分布。这种组合在理论上可能同时影响体重与血糖指标，但协同关系的细节仍处在研究阶段。
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Laboratories identify and quantify retatrutide using reversed-phase high-performance liquid chromatography coupled to mass spectrometry. This approach separates the peptide from related impurities and confirms identity through mass-to-charge measurements. Purity is commonly reported as the area percentage of the main peak relative to the total chromatogram. Ultraviolet detection near 214 nanometers is also used for peptide quantification, while intact mass analysis checks the molecular weight against a reference value.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
In 2009, IGN named Newell one of the top 100 game creators, writing that it was "almost impossible to gauge" Valve's influence on game design, technology and the video games industry. In December 2010, Forbes listed Newell as "A Name You Need to Know", primarily for his work on Steam and partnerships with multiple major developers. In 2013, Newell was added to the Academy of Interactive Arts & Sciences Hall of Fame and received the BAFTA Fellowship for his contributions to the video game industry. According to Josh Weier, the project lead for Portal 2 (2011), Newell became less involved in game development after Portal 2 as many developers would blindly agree with his ideas due to his position. As of 2024, Newell had become less involved in Valve and was spending more time on personal projects.
Stanniocalcin (originally named hypocalcin or teleocalcin or parathyrin) is a family of hormones which regulate calcium and phosphate balance in the body. The first stanniocalcin discovered was from fish and was identified as the principal calcium-reducing (hypocalcaemic) factor. It was isolated from special organs in fish called corpuscles of Stannius, hence the name stanniocalcin. Chemically, stanniocalcins are glycosylated proteins (i.e. proteins containing carbohydrate, or glycoproteins) having a molecular mass of 50 kDa. They exist in molecular pairs (homodimers) and are joined together by disulfide linkage. Stanniocalcins are made up of approximately 250 amino acids.
== See also == 3,4-Dihydroxyamphetamine (HHA; α-methyldopamine) 4-Hydroxy-3-methoxyamphetamine (HMA) 4-Hydroxy-3-methoxymethamphetamine (HMMA) 2,4,5-Trihydroxyamphetamine (THA) 2,4,5-Trihydroxymethamphetamine (THMA) 3,4-Dihydroxymethcathinone (HHMC) 4-Hydroxy-3-methoxymethcathinone (HMMC)
Sources: en.wikipedia.org
(1974), president of the University of the District of Columbia and former president of Southern University Reynold Verret (1976), president of Xavier University of Louisiana Gregory F. Ball (1977), psychologist, dean of the University of Maryland College of Behavioral and Social Sciences Thomas Worcester (1977), Jesuit academic, president of Regis College, Toronto, professor of the University of Toronto Alan Kadish (1977), president of the Touro College and University System Ralph Keen (1979), professor and dean of the honors college at the University of Illinois at Chicago Colin Crawford (1980), 24th dean of the University of Louisville School of Law and incoming dean of the Golden Gate University School of Law Samuel Hoi (1980), president of the Maryland Institute College of Art Daniel Gordis (1981), vice president of Shalem College, Israel's first liberal arts college Mark C. Gordon (1981), first president and dean of the Mitchell Hamline School of Law, former president of Defiance College and dean of the University of Detroit Mercy School of Law Donald S. Siegel (1981), economist and director of the School of Public Affairs at Arizona State University Deborah Waxman (1989), president of Reconstructionist Rabbinical College and Jewish Reconstructionist Communities Jonathan H.
She performed all of this contingency EVA. After 176 days, 1 hour, 18 minutes and 38 seconds in space, Caldwell Dyson landed in Kazakhstan on September 25, 2010. During this spaceflight, she completed three spacewalks, logging 22 hrs and 49 minutes of EVA work to replace a malfunctioning coolant pump.
== History == In May 2023, the China Manned Space Agency (CMSA) issued a public solicitation for proposals for a low-cost cargo transportation system. Key requirements included an upmass capacity of at least 1.8 tonnes (1.8 long tons; 2.0 short tons), a pressurized volume of at least 7 cubic metres (250 cu ft), the ability to remain docked for at least three months, a waste disposal capacity of at least 2 tonnes (2.0 long tons; 2.2 short tons), and a target cost of no more than 120 million RMB per ton. In September 2023, IAMCAS's proposal was selected as one of the four finalists from ten submissions. By October 2024, the CMSA announced that the Qingzhou spacecraft and the Haolong cargo spaceplane (developed by the Chengdu Aircraft Design Institute) had won the final competition and were awarded contracts for flight verification. On 30 March 2026, a prototype version of Qingzhou was launched on the maiden flight of CAS Space's Kinetica 2.
Sources: en.wikipedia.org
== J == Jacobsen epoxidation Jacobsen rearrangement Janovsky reaction Japp–Klingemann reaction Japp–Maitland condensation Jocic reaction Johnson–Claisen rearrangement Johnson–Corey–Chaykovsky reaction Jones oxidation Jordan–Ullmann–Goldberg synthesis Julia olefination, Julia–Lythgoe olefination
=== TNXB (functional gene) === The TNXB gene localizes to the major histocompatibility complex (MHC class III) region on chromosome 6. The structure of this gene is unusual in that it overlaps the CREBL1 and CYP21A2 genes at its 5' and 3' ends, respectively.
Eli Lilly also markets fluoxetine in a fixed-dose combination with olanzapine as olanzapine/fluoxetine (Symbyax), which was approved by the US Food and Drug Administration (FDA) for the treatment of depressive episodes of bipolar I disorder in 2003 and for treatment-resistant depression in 2009.
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。